207 related articles for article (PubMed ID: 16458386)
21. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells.
Theiner G; Rössner S; Dalpke A; Bode K; Berger T; Gessner A; Lutz MB
Mol Immunol; 2008 Jan; 45(1):244-52. PubMed ID: 17599410
[TBL] [Abstract][Full Text] [Related]
22. The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes.
de Jong SD; Basha G; Wilson KD; Kazem M; Cullis P; Jefferies W; Tam Y
J Immunol; 2010 Jun; 184(11):6092-102. PubMed ID: 20427776
[TBL] [Abstract][Full Text] [Related]
23. Molecular cloning and characterization of equine Toll-like receptor 9.
Zhang YW; Davis EG; Blecha F; Wilkerson MJ
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):209-19. PubMed ID: 18462806
[TBL] [Abstract][Full Text] [Related]
24. Effects of CpG-oligonucleotides, poly I:C and LPS on Atlantic cod scavenger endothelial cells (SEC).
Martin-Armas M; Zykova S; Smedsrød B
Dev Comp Immunol; 2008; 32(2):100-7. PubMed ID: 17560649
[TBL] [Abstract][Full Text] [Related]
25. Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma.
Erridge C; Burdess A; Jackson AJ; Murray C; Riggio M; Lappin D; Milligan S; Spickett CM; Webb DJ
Eur J Clin Invest; 2008 Oct; 38(10):713-20. PubMed ID: 18837796
[TBL] [Abstract][Full Text] [Related]
26. Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus.
Lindau D; Rönnefarth V; Erbacher A; Rammensee HG; Decker P
Eur J Immunol; 2011 Mar; 41(3):669-81. PubMed ID: 21287547
[TBL] [Abstract][Full Text] [Related]
27. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
28. Defect of toll-like receptor 9-mediated activation in NC/Nga mouse macrophages.
Sakai T; Kogiso M; Mitsuya K; Komatsu T; Yamamoto S
Immunol Lett; 2006 Jul; 106(1):91-5. PubMed ID: 16650483
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.
Brignole C; Marimpietri D; Di Paolo D; Perri P; Morandi F; Pastorino F; Zorzoli A; Pagnan G; Loi M; Caffa I; Erminio G; Haupt R; Gambini C; Pistoia V; Ponzoni M
Cancer Res; 2010 Dec; 70(23):9816-26. PubMed ID: 20935225
[TBL] [Abstract][Full Text] [Related]
30. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
Yu D; Putta MR; Bhagat L; Li Y; Zhu F; Wang D; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2007 Dec; 50(25):6411-8. PubMed ID: 17988082
[TBL] [Abstract][Full Text] [Related]
31. Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice.
Arteta B; Lasuen N; Lopategi A; Sveinbjörnsson B; Smedsrød B; Vidal-Vanaclocha F
Hepatology; 2010 Jun; 51(6):2172-82. PubMed ID: 20513002
[TBL] [Abstract][Full Text] [Related]
32. PU.1 and ICSBP control constitutive and IFN-gamma-regulated Tlr9 gene expression in mouse macrophages.
Schroder K; Lichtinger M; Irvine KM; Brion K; Trieu A; Ross IL; Ravasi T; Stacey KJ; Rehli M; Hume DA; Sweet MJ
J Leukoc Biol; 2007 Jun; 81(6):1577-90. PubMed ID: 17360957
[TBL] [Abstract][Full Text] [Related]
33. Chicken TLR21 is an innate CpG DNA receptor distinct from mammalian TLR9.
Keestra AM; de Zoete MR; Bouwman LI; van Putten JP
J Immunol; 2010 Jul; 185(1):460-7. PubMed ID: 20498358
[TBL] [Abstract][Full Text] [Related]
34. Full-length sequence and expression analysis of Toll-like receptor 9 in the gilthead seabream (Sparus aurata L.).
Franch R; Cardazzo B; Antonello J; Castagnaro M; Patarnello T; Bargelloni L
Gene; 2006 Aug; 378():42-51. PubMed ID: 16797882
[TBL] [Abstract][Full Text] [Related]
35. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
Wang D; Bhagat L; Yu D; Zhu FG; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2009 Jan; 52(2):551-8. PubMed ID: 19102653
[TBL] [Abstract][Full Text] [Related]
36. Granulin is a soluble cofactor for toll-like receptor 9 signaling.
Park B; Buti L; Lee S; Matsuwaki T; Spooner E; Brinkmann MM; Nishihara M; Ploegh HL
Immunity; 2011 Apr; 34(4):505-13. PubMed ID: 21497117
[TBL] [Abstract][Full Text] [Related]
37. Ncf1 provides a reactive oxygen species-independent negative feedback regulation of TLR9-induced IL-12p70 in murine dendritic cells.
Richter C; Juan MH; Will J; Brandes RP; Kalinke U; Akira S; Pfeilschifter JM; Hultqvist M; Holmdahl R; Radeke HH
J Immunol; 2009 Apr; 182(7):4183-91. PubMed ID: 19299716
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of TLR9 activation.
Latz E; Visintin A; Espevik T; Golenbock DT
J Endotoxin Res; 2004; 10(6):406-12. PubMed ID: 15588423
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptor 9-mediated cytosolic phospholipase A2 activation regulates expression of inducible nitric oxide synthase.
Lee SH; Lee JG; Kim JR; Baek SH
Biochem Biophys Res Commun; 2007 Dec; 364(4):996-1001. PubMed ID: 18273445
[TBL] [Abstract][Full Text] [Related]
40. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
Ilvesaro JM; Merrell MA; Swain TM; Davidson J; Zayzafoon M; Harris KW; Selander KS
Prostate; 2007 May; 67(7):774-81. PubMed ID: 17373717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
